Progression of Hypopituitarism and Hypothyroidism after Treatment with Pembrolizumab in a Patient with Adrenal Metastasis from Non-small-cell Lung Cancer-Reference-Cited by-同舟云学术

Progression of Hypopituitarism and Hypothyroidism after Treatment with Pembrolizumab in a Patient with Adrenal Metastasis from Non-small-cell Lung Cancer

Published:2019-12-15 Issue:24 Volume:58 Page:3557-3562
ISSN:0918-2918
Container-title:Internal Medicine
language:en
Short-container-title:Intern. Med.

Author:

Yamagata Satoshi¹,Kageyama Kazunori¹,Takayasu Shinobu¹,Asari Yuko¹,Makita Koshi¹,Terui Ken¹,Daimon Makoto¹

Affiliation:

1. Department of Endocrinology and Metabolism, Hirosaki University Graduate School of Medicine, Japan

Publisher

Japanese Society of Internal Medicine

Subject

General Medicine,Internal Medicine

Link

https://www.jstage.jst.go.jp/article/internalmedicine/58/24/58_3008-19/_pdf

Reference27 articles.

1. 1. Ishida Y, Agata Y, Shibahara K, Honjo T. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J 11: 3887-3895, 1992.

2. 2. Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 26: 677-704, 2008.

3. 3. Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci USA 99: 12293-12297, 2002.

4. 4. McDermott DF, Atkins MB. PD-1 as a potential target in cancer therapy. Cancer Med 2: 662-673, 2013.

5. 5. Byun DJ, Wolchok JD, Rosenberg LM, Girotra M. Cancer immunotherapy-immune checkpoint blockade and associated endocrinopathies. Nat Rev Endocrinol 13: 195-207, 2017.

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PD-1/PD-L1 inhibitors associated hypophysitis: An analysis from the FAERS database and case reports;Drug Discoveries & Therapeutics;2024-02-29

2. Pembrolizumab-induced secondary adrenal insufficiency due to adrenocorticotrophic hormone deficiency in a patient with non-small-cell lung carcinoma: a case report;Journal of Pharmaceutical Health Care and Sciences;2024-02-16

3. Clinical characteristics and potential biomarkers of thyroid and pituitary immune-related adverse events;Endocrine Journal;2024

4. Isolated adrenocorticotropic hormone deficiency associated with sintilimab therapy in a patient with advanced lung adenocarcinoma: a case report and literature review;BMC Endocrine Disorders;2022-09-24

5. Clinical course and management of insidious adrenal crisis manifested initially as hyperpyrexia secondary to pembrolizumab: Case reports and literature review;Frontiers in Oncology;2022-08-11